{"schema_version":"secwatch.filing_event.v1","accession":"0001672688-26-000134","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2026-08-11T20:06:14+00:00","discovered_at":"2026-08-11T20:08:04.396064+00:00","generated_at":"2026-08-11T20:08:56.204920+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering","bullets":["Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.","Completed $100M underwritten offering incl. $40M strategic investment from Eli Lilly; net proceeds $93.6M.","Cash and securities $201.1M at 6/30/26, up from $125.7M at 3/31/26; runway into H2 2028.","Q2 2026: revenue $0.3M (vs $0.6M YoY); net loss $33.2M (vs $30.6M YoY).","ABS-201 endometriosis Phase 2 planned Q4 2026; PHL proof-of-concept data H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001672688-26-000134","json":"https://secwatch.observer/filing/0001672688-26-000134.json","markdown":"https://secwatch.observer/filing/0001672688-26-000134.md","text":"https://secwatch.observer/filing/0001672688-26-000134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/0001672688-26-000134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/absc-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:08:56.204920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}